Pradaxa Heart Attack Risk
The risk of Pradaxa heart attack (myocardial infarction) has been identified in studies published by prominent medical journals and is now under investigation at the FDA. Clinical studies show that in addition to increasing the risk of a severe bleeding incident, Pradaxa heart attack risk is a real side effect of taking the drug.
On January 9, 2012, the Archive of Internal Medicine published a meta analysis of seven Pradaxa heart attack clinical trials that followed over 30,000 patients. The study compared patients taking Pradaxa to patients taking other blood thinners or placebo. Conducted by researchers at the Cleveland Clinic’s Department of Cardiology, the study revealed that Pradaxa use is, “significantly associated with a higher risk” of heart attack. Specifically, the study concluded that the risk of heart attack is 33% higher in patients taking Pradaxa than those taking other blood thinners or placebo. Patients who’ve had a heart attack while taking Pradaxa or their family members may have legal rights. Read below for more information or contact our Pradaxa heart attack lawyers for a free consultation.
Patients who require a blood thinner to treat atrial fibrillation statistically tend to face multiple risk factors for heart attack; introducing the danger of Pradaxa heart attack is a serious and potentially deadly increase in risk for such people. The study concluded that Pradaxa, “is associated with an increased risk” of heart attack “in a broad spectrum of patients when tested against different controls. Clinicians should consider the potential of these serious harmful cardiovascular effects”.
Medical Experts Declare Pradaxa Heart Attack Risk
Indeed, a growing group of medical professionals and researchers have acknowledged the danger of Pradaxa heart attacks. Corresponding to the time Pradaxa was first approved for stroke reduction by the FDA, an article was published in the New England Journal of Medicine, examining the overall risks and benefits of the drug. The risk of Pradaxa heart attack was identified then; the article states that Pradaxa causes an increased risk of myocardial infarction over warfarin anti coagulant drugs.
Another important voice, the clinical director of interventional cardiology research at Lenox Hill Hospital in New York, has also weighed in on the matter. Dr. Kirk Garratt, M.D., warns that “if I have a patient on this drug for ten years, I’d expect a 5% increased lifetime risk of heart attack.” Adding an increased risk for heart attack by taking Pradaxa can be the difference between life and death for some patients.
Pradaxa Heart Attack Lawyers Offer Assistance
Pradaxa heart attack lawyers are experts in legal cases pertaining to Pradaxa patients who have experienced heart attack. If you or a loved one fit that description, a Pradaxa hear t attack lawyer can answer your specific questions and tell you about your legal rights.
Despite the clear risk of heart attack connected with taking Pradaxa, patients who are currently taking the drug are advised to continue unless their doctor prescribes another blood thinner. More information will be made available on the subject when the FDA concludes its current study. Steve Nissen, chairman of the cardiology department responsible for the study published in 2012 urged regulators to take a serious look at the matter of Pradaxa heart attack risk, saying, “These data should be looked at cafefully by the regulatory community.”
Pradaxa Heart Attack Lawsuits
Pradaxa heart attack lawsuits are represented on a contingency basis, meaning that you pay nothing if you do not receive compensation. People who have experienced heart attack while taking Pradaxa may file a Pradaxa heart attack lawsuit or their loved ones may file a Pradaxa heart attack lawsuit on their behalf.
Pradaxa was first approved by the FDA to prevent stroke in people with non-valvular atrial fibrillation on October 19, 2010. It was intended to replace the drug warfarin, which has been the main drug used for this purpose since the 1950s. Early clinical trials showed that it was more effective at preventing stroke in patients with heart arrhythmia than warfarin. But despite Pradaxa’s potential benefits, many doctors and regulating bodies have warned against its use. The drug may have an unacceptably high level of risk, causing life-threatening Pradaxa internal bleeding and death. Furthermore, no effective treatment has been found to stop Pradaxa internal bleeding once it begins.
Patients who have chosen to take Pradaxa to avoid one life-threatening health condition, have often unknowingly introduced another serious and untreatable risk. If your loved one died as a result of taking Pradaxa, contact our lawyers to learn more about Pradaxa internal bleeding lawsuits and your legal rights. Pradaxa is sold by the German pharmaceutical company Boehringer Ingelheim and is still in wide use in the United States.
In response to high numbers of Pradaxa internal bleeding events that have been reported, the FDA required Boehringer Ingelheim to add a warning about bleeding risks to the product’s box in January of 2012. The federal regulating agency is conducting extensive research on the drug now, based on the large number of post-market Pradaxa internal bleeding deaths reported to the MedWatch program and worldwide.